Efficacy of Remimazolam for Anesthesia in Patients Undergoing Renal Allograft Transplantation: A Randomized Controlled Trial.

PURPOSE: As a novel benzodiazepine sedative, remimazolam has demonstrated favorable anesthetic properties. However, its clinical performance in patients undergoing renal allograft transplantation remains undetermined. This study aimed to evaluate the efficacy of remimazolam for anesthesia in patients undergoing renal allograft transplantation, with the incidence of hypotension during induction as the primary endpoint.

PATIENTS AND

METHODS

Sixty patients scheduled for elective living-related renal transplantation were enrolled. The participants were randomly allocated into two groups (n=30 each): the propofol group (Group P) and the remimazolam group (Group R). Groups P and R received propofol and remimazolam, respectively, for anesthesia induction and maintenance. The patients' hemodynamic parameters, postoperative recovery outcomes, adverse reactions, and pharmacokinetic parameters of the sedative drugs were recorded and compared between groups.

RESULTS

Compared with propofol, remimazolam has a longer onset time, but provides better hemodynamic stability, more rapid metabolism, negligible injection pain, and no significant impact on hepatic or renal function.

CONCLUSION

Despite its prolonged onset time, remimazolam provides better hemodynamic stability and less injection pain than propofol in patients undergoing allogeneic renal transplantation, with comparable recovery outcomes. Its rapid metabolism is evidenced by a prompt decline in plasma concentration following discontinuation.